Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm

Biogen Inc. (BIIB) announced plans to reprioritize its resources in Alzheimer’s disease (AD). It intends to advance the new Alzheimer’s drug Leqembi (lecanemab-irmb) and to accelerate the development of new treatment modalities.Alzheimer's is a progressive, fatal disease of the brain characterized by a decline in memory, language and other thinking skills, as well as changes in mood and behavior.As part of this reprioritization plan, Biogen will henceforth stop the development and commercialization of its c ...